Company to move forward with novel therapies for migraine and Parkinson’s disease
The technology could enable researchers to test drugs or treatments on a patient’s cells to avoid harmful, ineffective and costly options while determining personalized regimens.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SAGE-217 for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation granted to Sage since 2016.
HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
Scientists have created a hair-thin implant that can drip medications deep into the brain by remote control and with pinpoint precision.
Although it isn’t talked about often, older adults in the United States are turning to drugs and alcohol at an alarming rate. Studies have found that a large population of older Americans are suffering from substance use disorders, and the number is only expected to rise. According to research, the number of Americans aged 50 and older struggling with addiction is expected to nearly double in the coming years, going from 2.8 million to 5.7 million by 2020.
New research shows that wearables and remote patient monitoring technology have a limited impact on clinical outcomes. But digital health researchers aren't ready to abandon the promise of mobile technology.
Stem cells have the unique capability to transform into any sort of specialized cell needed in the body, making them especially promising for medicine that replaces nonfunctional or dead cells.
The experimental drug J147 is something of a modern elixir of life; it’s been shown to treat Alzheimer’s disease and reverse aging in mice and is almost ready for clinical trials in humans.
New drug approvals all but screeched to a halt in 2016, with a measly 22 new OKs after a pair of bountiful years. But the FDA wasted no time in 2017, signing off on 12 drugs in the first quarter alone—besting its record for the same period of any year in recent history.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.